WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical firm pioneering the invention and growth of a brand new technology of immuno-oncology therapeutics for sufferers, right this moment introduced a poster presentation of preclinical information on EOS-984, a possible first-in-class small molecule inhibitor concentrating on the equilibrative nucleoside transporter 1 (ENT1) in oncology, on the American Affiliation for Most cancers Analysis (AACR) Annual Assembly, being held April 5-10, 2024 in San Diego, California.
Based mostly on the Firm’s discovery and characterization of ENT1 in adenosine-mediated immunosuppression, this novel mechanism permits for the intracellular accumulation of adenosine, which then suppresses proliferation and effector perform of T cells within the excessive adenosine tumor microenvironment. In mouse fashions, deletion of ENT1 led to potent management of tumor proliferation and elevated CD8+ T cell frequency, proliferation, and cytokine manufacturing inside tumors, additional supporting ENT1’s position in tumor development. In preclinical research, blockade of intracellular adenosine accumulation by EOS-984 enabled proliferation of reminiscence T cells and TILs regardless of excessive adenosine concentrations, ensuing within the restoration of T cell perform and enhanced tumor cell killing. Moreover, mixture of EOS-984 with anti-PD-1 remedy synergistically led to the management of tumor development in a humanized mouse mannequin of triple unfavourable breast most cancers immune to anti-PD-1 blockade. As a consequence of its mechanism of motion, EOS-984 holds potential as a mixture companion past anti-PD-1 remedy, together with different immuno-oncology brokers, cell therapies, and bispecific T cell engagers.
EOS-984 is at the moment within the dose escalation portion of a Section 1 trial in superior malignancies. Topline information from the Section 1 trial is anticipated within the second half of 2024.
Abstracts can be found on AACR’s web site positioned at www.aacr.org. Posters shall be archived within the Traders part of the Firm’s web site positioned at www.iteostherapeutics.com.
Poster Presentation Particulars
Title: “Inhibition of equilibrative nucleoside transporter 1 relieves intracellular adenosine-mediated immune suppression”
Session Title: Experimental and Molecular Therapeutics: Tumor Microenvironment
Summary Quantity: 734
Date and Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Part 29
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical firm pioneering the invention and growth of a brand new technology of immuno-oncology therapeutics for sufferers. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to revive the immune response towards most cancers. The Firm’s modern pipeline consists of three clinical-stage applications concentrating on novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved scientific outcomes, together with the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a analysis middle in Gosselies, Belgium.
About EOS-984
EOS-984 is a possible first-in-class small molecule concentrating on the equilibrative nucleoside transporter 1 (ENT1) designed to inhibit the immunosuppressive exercise of adenosine and restore immune cell proliferation. The therapeutic candidate has the potential to completely reverse the profound immunosuppressive motion of adenosine on T and B cells and is in Section 1 growth.
Web Posting of Data
iTeos Therapeutics routinely posts data that could be necessary to buyers within the ‘Traders’ part of its web site at www.iteostherapeutics.com. The corporate encourages buyers and potential buyers to seek the advice of our web site recurrently for necessary details about iTeos Therapeutics.
Ahead-Wanting Statements
This press launch comprises forward-looking statements. Any statements that aren’t solely statements of historic reality are forward-looking statements. Phrases reminiscent of “consider,” “anticipate,” “plan,” “anticipate,” “will,” “could,” “intend,” “put together,” “look,” “potential,” “potential” and related expressions are supposed to establish forward-looking statements. These forward-looking statements embrace statements regarding the potential advantages of EOS-984, the potential of EOS-984 to be first-in-class, and EOS-984’s potential as a mixture companion past anti-PD-1 remedy, together with different immuno-oncology brokers, cell therapies, and bispecific T cell engagers.
These forward-looking statements contain dangers and uncertainties, lots of that are past iTeos’ management. Precise outcomes might materially differ from these said or implied by these forward-looking statements on account of such dangers and uncertainties. Recognized threat components embrace the next: success in preclinical testing and early scientific trials doesn’t make sure that later scientific trials shall be profitable; the info for our product candidates is probably not enough for acquiring regulatory approval to maneuver into later stage trials or to commercialize merchandise; iTeos could not have the ability to execute on its enterprise plans, together with assembly its anticipated or deliberate regulatory milestones and timelines, analysis and scientific growth plans, and bringing its product candidates to market, for varied causes, a few of which can be outdoors of iTeos’ management, together with potential limitations of firm monetary and different assets, manufacturing limitations that is probably not anticipated or resolved for in a well timed method, unfavourable developments within the discipline of immuno-oncology, reminiscent of opposed occasions or disappointing outcomes, together with in reference to competitor therapies, and regulatory, court docket or company selections reminiscent of selections by the US Patent and Trademark Workplace with respect to patents that cowl our product candidates; and people dangers recognized below the heading “Threat Components” in iTeos’ Annual Report on Type 10-Okay for the yr ended December 31, 2023 filed with the Securities and Change Fee (SEC) in addition to different SEC filings made by the Firm which you’re inspired to evaluate.
Any of the foregoing dangers might materially and adversely have an effect on iTeos’ enterprise, outcomes of operations and the buying and selling worth of iTeos’ frequent inventory. We warning buyers to not place appreciable reliance on the forward-looking statements contained on this press launch. iTeos doesn’t undertake any obligation to publicly replace its forward-looking statements apart from as required by regulation.
For additional data, please contact:
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
The put up iTeos Presents EOS-984 Preclinical Knowledge Demonstrating Restoration of T Cell Exercise from Adenosine Suppression on the American Affiliation for Most cancers Analysis Annual Assembly 2024 appeared first on DailyBusiness.